Guillain-Barré syndrome natural history, complications, and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Guillain-Barré syndrome}}
{{Guillain-Barré syndrome}}


{{CMG}}; '''Associate Editors-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]
{{CMG}}; '''Associate Editors-In-Chief:''' {{Fs}}


==Overview==
==Overview==

Revision as of 19:29, 14 December 2018

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome natural history, complications, and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome natural history, complications, and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome natural history, complications, and prognosis

CDC on Guillain-Barré syndrome natural history, complications, and prognosis

Guillain-Barré syndrome natural history, complications, and prognosis in the news

Blogs on Guillain-Barré syndrome natural history, complications, and prognosis

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome natural history, complications, and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Fahimeh Shojaei, M.D.

Overview

Approximately 80% of patients have a complete recovery within a few months to a year, although minor findings may persist. A patient's outcome is most likely to be very good when the symptoms go away within 3 weeks after they first started. Complications like paralysis, respiratory failure and hypotension can be seen in these patients.

Natural History, Complications, and Prognosis

Natural history

  • Most of the time recovery starts after 4th week from the onset of the disease.
  • Approximately 80% of patients have a complete recovery within a few months to a year, although minor findings may persist, such as areflexia.
  • About 5-10% recover with severe disability, with most of such cases involving severe proximal motor and sensory axonal damage with inability of axonal regeneration.
  • However, this is a grave disease and despite all improvements in treatment and supportive care, the death rate among patients with this disease is still about 2-3% even in the best intensive care units.
  • Worldwide, the death rate runs slightly higher (4%), mostly from a lack of availability of life support equipment during the lengthy plateau lasting 4 to 6 weeks, and in some cases up to 1 year, when a ventilator is needed in the worse cases.
  • About 5-10% of patients have one or more late relapses, in which case they are then classified as having chronic inflammatory demyelinating polyneuropathy (CIDP).

Complications

Prognosis

  • About 65% of patients with GBS will fully recover with no permanent disability.
  • 35% of them do not fully recover. 8% of this group will die from GBS complication and others will have permanent disabilities.
  • Treatment of GBS just reduce the recovery time and doesn’t affect prognosis.
  • Overally, older patients will have worst prognosis in comparison to children who discover very fast.

References

  1. Dornonville de la Cour C, Jakobsen J (January 2005). "Residual neuropathy in long-term population-based follow-up of Guillain-Barré syndrome". Neurology. 64 (2): 246–53. doi:10.1212/01.WNL.0000149521.65474.83. PMID 15668421.
  2. Meythaler JM (August 1997). "Rehabilitation of Guillain-Barré syndrome". Arch Phys Med Rehabil. 78 (8): 872–9. PMID 9344309.

Template:WH Template:WS